A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown.
The effectiveness of radiotherapy treatment could be significantly improved if tumor cells could be rendered more sensitive to ionizing radiation (IR) without altering the sensitivity of normal tissues. However, many of the key therapeutically exploitable mechanisms that determine intrinsic tumor radiosensitivity are largely unknown. We have conducted a small interfering RNA (siRNA) screen of 200 genes involved in DNA damage repair aimed at identifying genes whose knockdown increased tumor radiosensitivity. Parallel siRNA screens were conducted in irradiated and unirradiated tumor cells (SQ20B) and irradiated normal tissue cells (MRC5). Using gammaH2AX foci at 24 hours after IR, we identified several genes, such as BRCA2, Lig IV, and XRCC5, whose knockdown is known to cause increased cell radiosensitivity, thereby validating the primary screening end point. In addition, we identified POLQ (DNA polymerase ) as a potential tumor-specific target. Subsequent investigations showed that POLQ knockdown resulted in radiosensitization of a panel of tumor cell lines from different primary sites while having little or no effect on normal tissue cell lines. These findings raise the possibility that POLQ inhibition might be used clinically to cause tumor-specific radiosensitization.
Gray Institute for Radiation Oncology and Biology, Oxford University, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
Geoff S
GS
Higgins
Remko
R
Prevo
Yin-Fai
YF
Lee
Thomas
T
Helleday
Ruth J
RJ
Muschel
Steve
S
Taylor
Michio
M
Yoshimura
Ian D
ID
Hickson
Eric J
EJ
Bernhard
W Gillies
WG
McKenna
D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000235:genetics / Q000528:radiation effects; D004260:DNA Repair / Q000235:genetics*; D004259:DNA-Directed DNA Polymerase / Q000172:deficiency / Q000235:genetics* / Q000378:metabolism; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000494:pharmacology; D055785:Gene Knockdown Techniques; D006367:HeLa Cells; D006657:Histones; D006801:Humans; D007259:Infrared Rays; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000532:radiotherapy*; D034741:RNA, Small Interfering / Q000235:genetics*; D011836:Radiation Tolerance / Q000235:genetics; D000077204:Temozolomide; D014162:Transfection; D000097462:DNA Polymerase theta
D018906:Antineoplastic Agents, Alkylating; D004259:DNA-Directed DNA Polymerase; D003606:Dacarbazine; D006657:Histones; D034741:RNA, Small Interfering; D000077204:Temozolomide; D000097462:DNA Polymerase theta; C468783:H2AX protein, human